Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.27 (market cap $2.14B), while Vanguard Real Estate Index Fund ETF trades at $90.53 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 33.1× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| RXRX | VNQ | |
|---|---|---|
Market Cap | $2.14B | $70.80B |
Volume | 30,789,535 | 6,073,580 |
Sector | Health | — |
52-Week High | $6.79 | $100.95 |
52-Week Low | $2.84 | $87.00 |
Typical Hold Time | 22 Days | 113 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
VNQ trades at $90.50, up 2.04% today but facing a bearish technical trend with key support at $87. The ETF's fundamentals are obscured by missing valuation ratios, while sentiment is mixed amid rising interest rates pressuring REIT yields. Recent news highlights institutional buying but also concerns over dividend sustainability versus Treasury bills.
Outlook remains cautious due to interest rate sensitivity and sector oversupply risks. Opportunities exist for contrarian investors seeking long-term real estate exposure, but near-term headwinds from Fed policy and economic volatility warrant careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
